key: cord-0702633-8d7my5v5
authors: Elzeneini, Mohammed; Al-Ani, Mohammad; Peters, Anthony E.; Burdick, Marie D.; Yang, Ning; Salerno, Michael; Mehrad, Borna; Keeley, Ellen C.
title: Circulating fibrocyte levels correlate with infarct size in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention()
date: 2021-11-27
journal: Am Heart J Plus
DOI: 10.1016/j.ahjo.2021.100071
sha: 36f4c9e6abfc62f951b0f8cedf09ea0483e32d06
doc_id: 702633
cord_uid: 8d7my5v5

STUDY OBJECTIVE: Infarct size is a strong predictor of outcomes after ST elevation myocardial infarction (STEMI). Circulating fibrocytes are bone marrow-derived progenitor cells associated with fibrotic processes. We tested whether fibrocytes correlate with infarct size in STEMI patients treated with primary percutaneous coronary intervention (PCI). DESIGN: Prospective observational study. SETTING: Academic medical center. PARTICIPANTS: Subjects with STEMI treated with primary PCI. INTERVENTIONS: Peripheral blood draw and cardiac magnetic resonance imaging (CMR). MAIN OUTCOME MEASURE: Correlation of fibrocyte levels with infarct size. METHODS: Peripheral blood fibrocytes were quantified at discharge from STEMI hospitalization and at 6 months follow-up using flow cytometry. Infarct size was determined within 2 weeks of discharge and at 6 months follow-up using late gadolinium enhancement on CMR. RESULTS: Among 14 patients (median age 54 years, 79% men) with STEMI, there was a statistically significant positive correlation between fibrocyte levels at 6 months and 6-month infarct size on CMR (r = 0.58, p = 0.031). In addition, there was positive correlation between peak troponin I level (r = 0.85, p < 0.001), and white blood cell count (r = 0.55, p = 0.042) during the hospital stay and 6-month infarct size on CMR. CONCLUSIONS: Circulating fibrocytes measured 6 months after STEMI positively correlate with 6-month infarct size assessed by CMR.

In patients with ST elevation myocardial infarction (STEMI) treated with reperfusion therapy, the infarct area initially contains infarcted tissue, edema, swollen cardiomyocytes, and variable areas of micro-hemorrhage. Over several weeks, inflammation resolves and the infarcted tissue is replaced by extracellular matrix proteins that are then cross-linked, forming the mature myocardial scar [1] . The size of this fibrotic area, as detected by late gadolinium enhancement on cardiac magnetic resonance (CMR) imaging, is a strong predictor of clinical outcomes [2] . While CMR is a powerful tool to assess this process [3] , it is not routinely performed following STEMI in clinical practice [4] .

Circulating fibrocytes are bone marrow-derived progenitor cells that are released into the bloodstream in response to tissue injury and mediate tissue fibrosis [5] [6] [7] and can be quantified as an easily measurable biomarker of fibrosis. Fibrocytes have been shown to home to the injured myocardium in patients with myocardial infarction [8] , and the concentration of circulating fibrocytes is elevated in several fibrotic heart diseases [9, 10] . We thus hypothesized that, in patients with STEMI, circulating fibrocyte levels correlate with infarct size on CMR at 6 months.

This study was carried out in concordance with the principles of the Declaration of Helsinki and with approval of institutional review boards. We enrolled consecutive patients presenting with STEMI treated with primary PCI from August 1, 2014 to September 30, 2019. Inclusion criteria were: (1) age older than 18 years; (2) diagnosis of STEMI; and (3) treatment with primary PCI. Exclusion criteria were: (1) history of prior acute coronary syndrome; (2) known fibrotic disease or malignancy; (3) active infection; (4) surgery or trauma within the prior 6 weeks; (5) renal insufficiency (glomerular filtration rate < 45 ml/min/1.73m 2 ); (6) contrast allergy; and (7) any other contraindication to CMR. Baseline demographic data including age, gender, co-morbidities, laboratory values, angiographic information, echocardiographic results and medications were collected. Patients were treated with standard guideline-directed medical therapy at the discretion of their primary cardiologist.

Peripheral venous blood samples were collected in heparinized tubes prior to hospital discharge and at 6 months follow-up, and the concentration of fibrocytes was measured as previously described [11, 12] . Briefly, the buffy coat was filtered and the concentration of leukocytes quantified by enumerating live cells under a hemocytometer. Fibrocytes were identified by flow cytometry on a FACS Canto-II flow cytometer using Diva software (version 5.0.3; BD Biosciences), defined as cells co-expressing the common leukocyte antigen CD45, CD34, and intracellular staining for collagen-1 (CD45+ CD34+ Col1+). The absolute concentration was determined as the product of the ratio to parent CD45+ population and the concentration of live leukocytes in each sample.

Patients underwent CMR imaging within 2 weeks of discharge and at 6 months follow-up using previously published techniques [13] . Cine left ventricular function was assessed from end-diastolic and end-systolic volumes. Late gadolinium enhancement (LGE) imaging was obtained 10-15 min after injection of 0.15 mmol/kg of gadolinium contrast. Images were analyzed by MRI-trained cardiologists (MS and MA) blinded to patient fibrocyte data. For quantification of LGE, endocardial and epicardial borders were traced in a semi-automated fashion. Hyper-enhanced areas were detected in comparison with remote segments using full-width-half-maximum method. Manual correction was used to avoid blood pool detection and to include areas of microvascular obstruction. Infarct size was then recorded as the percentage of LGE areas from total left ventricular mass.

Data were analyzed in SPSS (version 26 for Mac, IBM, Armonk, New York, USA) or Prism (version 9 for Mac, GraphPad, San Diego, CA, USA) software. Continuous variables were summarized as median and inter-quartile range, and compared using the Mann-Whitney U test. Correlations were assessed using Pearson's correlation coefficient (r). Results were considered statistically significant if two-sided p value was less than 0.05.

Among 19 enrolled patients, 5 patients did not complete CMR due to claustrophobia (n = 1), COVID-19 restrictions regarding clinical research (n = 1), and relocation (n = 3). A total of 14 patients completed peripheral blood sampling and CMR imaging at baseline and follow-up and were included in the analysis (Table 1) . CMR data and fibrocyte levels at baseline and 6 months are summarized in Table 2 . No patients were rehospitalized or experienced major adverse cardiac events during the study period.

The concentration of circulating fibrocytes 6 months after STEMI had no detectable relationship with peak troponin I level, peak white blood cell count or left ventricular function during the hospital stay (Table 3) , but positively correlated with 6-month infarct size on CMR (Fig. 1, panel A) . Peak troponin I level (Fig. 1, panel B) and peak white blood cell count (Fig. 1, panel C) during the hospital stay both positively correlated with infarct size at 6 months, although left ventricular function did not ( Table 4 ). The presence of left anterior descending artery as a culprit for STEMI also positively correlated with infarct size at 6 months (r 0.57, p 0.034). There was no correlation between the change in EF and change in fibrocyte level over time (r 0.27, p 0.354).

We found that the concentration of circulating fibrocytes 6 months after STEMI correlated with the size of infarction on CMR. Consistent with prior literature, we also found a positive correlation between peak troponin and white blood cell count during hospital stay with 6-month infarct size [14] [15] [16] , consistent with the concept that, in the days following STEMI, higher white blood cell counts and troponin levels are indicative of a larger infarction.

Fibrocytes have been linked to normal wound healing as well as numerous fibrotic disorders [5] . As related to the heart, circulating fibrocytes correlated with LGE on CMR in patients with hypertrophic cardiomyopathy [9] and hypertensive heart disease [10] , left atrial fibrosis in patients with atrial fibrillation [17] , and myocardial infarction in murine models [18, 19] . In an autopsy study of patients who died of sudden death, investigators detected fibrocytes in the myocardium in areas of scar suggesting that fibrocytes migrate to the heart and contribute to myocardial fibrosis [20] . In a previously published study, investigators measured fibrocytes in thrombi aspirated from the infarct-related artery at the time of reperfusion and from a peripheral vein in STEMI patients undergoing primary PCI and found that fibrocytes were significantly increased in the infarct-related artery compared to the peripheral vein [8] .

Our finding that STEMI patients who have an elevated fibrocyte levels at 6 months have larger infarct size on CMR at 6 months adds to the concept that the concentration of circulating fibrocytes correlates with subsequent myocardial scar formation. While left ventricular systolic ejection fraction is an important predictor of clinical outcomes in STEMI patients [21] , ventricular function and chamber geometry are dependent on alterations within the extracellular matrix that occur during the reparative and adverse remodeling response [22] . The fact that fibrocyte counts at 6 months had no detectable relationship to peak troponin and white blood cell counts during hospitalization suggests that they are a measure of the fibrotic response to injury, rather than the magnitude of the infarction. If validated in a larger study, fibrocyte levels may be used as a biomarker of infarct size and a non-invasive blood test that can be used to assess the response to therapy with renin-angiotensin-aldosterone system inhibitors which are standard post-STEMI medications with anti-fibrotic properties.

Although our subjects were highly phenotyped and served as their own controls, we recognize the small size of this study as a limitation. The small sample size limited the ability to perform a multivariable analysis and makes our results only hypothesis-generating, Second, we only included patients undergoing primary PCI for STEMI therefore our results may not be generalizable to those treated with thrombolytic therapy. Third, our results suggest an association between circulating fibrocytes and infarct size but do not establish a causal relationship. Finally, we assessed for correlation between macroscopic fibrosis by late gadolinium enhancement (infarct size) and circulating fibrocyte levels; our study does not address remote (microscopic) myocardial fibrosis after MI.

In STEMI patients treated with primary PCI, circulating levels of fibrocytes at 6 months positively correlate with infarct size on CMR at 6 months. If validated in larger studies, circulating fibrocyte levels may be useful as a risk stratification tool, or as a target of response to therapy.

This work was supported by the American Heart Association award number 16IRG27180006 (E.C.K.)

Scatterplots showing correlations between fibrocyte levels and infarct size at 6 months (r = 0.58, p = 0.031) (panel A), peak troponin I level and infarct size (r = 0.85, p < 0.001) (panel B), and peak white blood cell count and infarct size (r = 0.55, p = 0.042) (panel C). LVEF = left ventricular ejection fraction. Cardiac functional assessment, myocardial scar, and fibrocyte levels at baseline and 6 month follow-up. Table 3 Correlation of variables with fibrocyte levels at baseline and 6 month follow-up. Table 4 Correlation of variables with infarct size at baseline and 6 month follow-up. Am Heart J Plus. Author manuscript; available in PMC 2022 January 24.

The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis

Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study

Assessment of myocardial fibrosis with cardiovascular magnetic resonance

Cardiovascular magnetic resonance in acute STsegment-elevation myocardial infarction: recent advances, controversies, and future directions

The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders

Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease

Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease

Neutrophil extracellular traps and fibrocytes in STsegment elevation myocardial infarction

Associations between fibrocytes and postcontrast myocardial T1 times in hypertrophic cardiomyopathy

Elevated circulating fibrocyte levels in patients with hypertensive heart disease

Circulating fibrocytes as biomarker of prognosis in hermansky-pudlak syndrome

Circulating fibrocytes as predictors of adverse events in unstable angina

Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease

Peak and fixed-time high-sensitive troponin for prediction of infarct size, impaired left ventricular function, and adverse outcomes in patients with first ST-segment elevation myocardial infarction receiving percutaneous coronary intervention

Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials

Relation between white blood cell count and final infarct size in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI trial)

Elevated circulating fibrocytes is a marker of left atrial fibrosis and recurrence of persistent atrial fibrillation

Bone marrow-derived cells contribute to infarct remodelling

Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction

Fibrocytes are associated with the fibrosis of coronary heart disease

Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction complicated with cardiogenic shock

The inflammatory response in myocardial injury, repair and remodeling